Home
/
Aptevo Therapeutics Inc.
/
Financials
/
Quarterly
Aptevo Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Aptevo Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2023
Sep 30, 2022
$3.11M
Nov 14, 2023
Q2
2023
Jun 30, 2022
$3.11M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$3.11M
May 11, 2023
Q3
2022
Sep 30, 2021
$3.10M
Nov 10, 2022
Q2
2022
Jun 30, 2021
$3.11M
Aug 11, 2022
Q1
2022
Mar 31, 2021
$2.42M
May 12, 2022
Q3
2021
Sep 30, 2020
$1.46M
Nov 12, 2021
Q2
2021
Jun 30, 2020
$473.0K
Aug 12, 2021
Q3
2019
Sep 30, 2019
$9.01M
Nov 7, 2019
Q2
2019
Jun 30, 2019
$7.36M
Aug 9, 2019
Q1
2019
Mar 31, 2019
$7.02M
May 9, 2019
Q3
2019
Sep 30, 2018
$5.82M
Nov 7, 2019
Q2
2019
Jun 30, 2018
$6.83M
Aug 9, 2019
Q1
2019
Mar 31, 2018
$4.07M
May 9, 2019
Q3
2018
Sep 30, 2017
$6.17M
Nov 14, 2018
Q2
2018
Jun 30, 2017
$3.53M
Aug 9, 2018
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$4.07M
May 10, 2018
Q3
2017
Sep 30, 2017
$6.17M
Nov 13, 2017
Q2
2017
Jun 30, 2017
$10.76M
Aug 10, 2017
Q1
2018
Mar 31, 2017
$2.14M
May 10, 2018
Q3
2017
Sep 30, 2016
$2.82M
Nov 13, 2017
Q2
2017
Jun 30, 2016
$10.19M
Aug 10, 2017
Q1
2017
Mar 31, 2016
$8.07M
May 12, 2017
Q3
2016
Sep 30, 2015
$6.56M
Nov 14, 2016
Q2
2016
Jun 30, 2015
$7.09M
Sep 22, 2016
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.55M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
($6.20M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($6.20M)
Aug 11, 2025
Q3
2025
Mar 31, 2025
($6.41M)
Nov 6, 2025
Q1
2025
Mar 31, 2025
($6.41M)
May 15, 2025
Q2
2025
Mar 31, 2025
($6.41M)
Aug 11, 2025
Q3
2025
Sep 30, 2024
($5.10M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($5.88M)
Aug 11, 2025
Q3
2025
Jun 30, 2024
($5.88M)
Nov 6, 2025
Q2
2025
Mar 31, 2024
($6.83M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($6.83M)
May 15, 2025
Q3
2025
Mar 31, 2024
($6.83M)
Nov 6, 2025
Q3
2024
Sep 30, 2023
($6.33M)
Nov 7, 2024
Q3
2024
Jun 30, 2023
($7.95M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($7.95M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
$2.77M
Nov 7, 2024
Q2
2024
Mar 31, 2023
$2.77M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$2.77M
May 8, 2024
Q3
2023
Sep 30, 2022
($7.64M)
Nov 14, 2023
Q3
2023
Jun 30, 2022
$28.01M
Nov 14, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.61M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($6.23M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($6.48M)
May 15, 2025
Q3
2025
Sep 30, 2024
($5.21M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($6.02M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($6.98M)
May 15, 2025
Q3
2024
Sep 30, 2023
($6.56M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($8.18M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($7.76M)
May 8, 2024
Q3
2023
Sep 30, 2022
($7.78M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($7.56M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($5.61M)
May 11, 2023
Q3
2022
Sep 30, 2021
($4.75M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($5.72M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($6.89M)
May 12, 2022
Q3
2021
Sep 30, 2020
($6.25M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($6.81M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($7.62M)
May 11, 2021
Q3
2020
Sep 30, 2019
($11.46M)
Nov 10, 2020
Q2
2019
Jun 30, 2019
($12.90M)
Aug 9, 2019